SIOUX FALLS, S.D., April 27, 2017 /PRNewswire/ -- Allergan recently announced that it has received FDA approval for TrueTear™ Intranasal Tear Neurostimulator, the first and only FDA-cleared device developed to temporarily increase tear production in adult patients.
"The FDA approval of the TrueTear™ brings new hope to patients suffering from dry eye," says Dr. Vance Thompson. "With the approval, we can now offer our patients an unprecedented solution for their dry eye. We are super excited about this technology."
When it comes to comfortable vision, there is nothing better than your own tears. TrueTear™ helps you create more tears so your DryEye syndrome can heal naturally.
Vance Thompson Vision was one of the first US research sites for this device. TrueTear™ helps stimulate production of multiple layers of the tear film.
"This represents a breakthrough in dry eye as the TrueTear™ delivers a non-invasive and drug free way to increase tear production," says Dr. Alison Tendler. "We are excited to be able to offer new innovations to our patients."
TrueTear™ is the first of its kind to provide a temporary increase in tear production during neurostimulation. The new advancement is an addition to Allergan's current eye care portfolio. Last May, Allergan announced positive results from two pivotal trials for TrueTear™ that showed an increase in tear production upon nasal neurostimulation in adults with aqueous tear deficiency.
"We are proud to have performed the very first cases in these studies," says Dr. John Berdahl. "This is further evidence that people who suffer from dry eye really look forward to solutions like these."
At Vance Thompson Vision, we know how important it is to wake up each morning to clear vision. Because improved sight means more than seeing your best. It means being your best. With more than 80,000 procedures and nearly 100 years of combined experience in eye care and refractive surgery, the team at Vance Thompson Vision is committed to using only the most advanced technology and sets standards used all over the globe for vision correction. For more information, visit www.vancethompsonvision.com.
CEO: Sioux Falls, SD
(605) 371-7120 / email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/at-vance-thompson-vision-new-dry-eye-fda-approval-leads-where-no-one-expected-up-your-nose-300447540.html
SOURCE Vance Thompson Vision